Overview

Provides a detailed survey of therapies for autoimmune diseases, exploring the rationale for their use and clinical data regarding their potential benefit.

Full Product Details

Author:   Vibeke Strand ,  David L. Scot ,  Lee S. Simon
Publisher:   Taylor & Francis Inc
Imprint:   CRC Press Inc
Dimensions:   Width: 21.00cm , Height: 2.30cm , Length: 28.00cm
Weight:   0.589kg
ISBN:  

9780824797485

ISBN 10:   0824797485
Pages:   332
Publication Date:   19 September 1996
Audience:   College/higher education ,  Professional and scholarly ,  Undergraduate ,  Postgraduate, Research & Scholarly
Format:   Hardback
Publisher's Status:   Active
Availability:   In Print  
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

Introduction The Evaluation of Biological Agents, Vibeke Strand and David L. Scott Cellular Targeted Therapies Anti-CD5 Ricin A Chain Immunoconjugate Therapy in Rheumatoid Arthritis, John J. Cash Early Clinical Studies of IL-2 Fusion Toxin in Patients with Severe Rheumatoid Arthritis Recent-Onset Insulin-Dependent Diabetes Mellitus, and Psoriasis, Thasia G. Woodworth and Karen Parker Chimeric Anti-CD4 Antibody as a Potential Therapeutic Agent for Rheumatoid Arthritis, Larry W. Moreland and William J. Koopman CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis, F. C. Breedveld The Use of CE9.1, a Primatized Monoclonal Anti-CD4, in the Treatment of Rheumatoid Arthritis, David E. Yocum, Alan M. Solinger, and John Lipani CAMPATH-1H Therapy in Autoimmune Diseases, Richard A. Watts and John D. Isaacs CAMPATH-1H in Rheumatoid Arthritis: United States Experience, David E. Yocum and Jeffrey M. Johnston Cytokine Targeted Therapies Interferon-Gamma in the Treatment of Rheumatoid Arthritis, Eric M. Veys, Herman Mielants, and Gust Verbruggen Tumor Necrosis Factor Blockade in Rheumatoid Arthritis, Michael J. Elliott, Marc Feldmann, and Ravinder N. Maini Engineered Human Anti-Tumor Necrosis Factor-Alpha (TNFaAntibody, CDP571, in Rheumatoid Arthritis, Ernest H. S. Choy and Gabriel S. Panayi Clinical Experience with Recombinant Human Interleukin-1 Receptor Type I (Rhu IL-1RI) in Patients with Rheumatoid Arthritis, Richard M. Pope, Barbara Drevlow, Jennifer Capezio, Rosa Lovis, and Alan Landay Treatment of Rheumatoid Arthritis with Soluble Tumor Necrosis Factor Receptor, Gary R. Margolies, William J. Koopman, and Larry W. Moreland Adhesion Molecule Targeted Therapies Treatment of Rheumatoid Arthritis with a Monoclonal Antibody to Intercellular Adhesion Molecule-1, Arthur F. Kavanaugh and Peter E. Lipsky Potential Antigen-Specific Therapies T-Cell-Receptor Peptide Therapy for Multiple Sclerosis, Arthur A. Vanderbark, Dennis N. Bourdette, Ruth H. Whitham, and Halina Offner T-Cell Receptor Peptide Vaccination Studies in Rheumatoid Arthritis, Louis W. Heck, Larry W. Moreland, and William J. Koopman Oral Tolerance for the Treatment of Autoimmune Disease, David A Hafler and Howard L. Weiner Oral Tolerance, David E. Trentham Intravenous Immunoglobulin (IVIg) in the Treatment of Autoimmune Diseases, Vibeke Strand and Martin L. Lee Purine and Pyrimidine Synthesis Inhibitors Inhibitors of De Novo Nucleotide Synthesis in the Treatment of Rheumatoid Arthritis, Robert I. Fox and Randall E. Morris Leflunomide: A New Immunosuppressive Drug, David L. Scott and Vibeke Strand Future Directions An Assessment of Novel Agents in the Treatment of the Rheumatic Diseases, Vibeke Strand and Lee S. Simon

Reviews

Author Information

Vibeke Strand, David L. Scot, Lee S. Simon

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions